New York University granted Regulus Therapeutics exclusive rights to NYU miR-33a and miR-33b therapeutic IP for metabolic diseases

New York University

U.S. / Academic

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Regulus Therapeutics Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced